Selected research
Market Outlook & Growth Opportunities
Global Glipizide Market Outlook and Growth Opportunities 2026
Market perspective
The global Glipizide market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Glipizide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Glipizide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Glipizide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Glipizide market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Glipizide market include CCPC, TEVA, Lukang Pharma, United Laboratories, Jumpcan, Pfizer, PIDI, Disha Pharma and Jingfeng Zhiyao, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Glipizide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Glipizide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Glipizide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Glipizide market size, projected growth trends, production technologies, key applications, and end-use industries.
Glipizide Segment by Company
CCPC
TEVA
Lukang Pharma
United Laboratories
Jumpcan
Pfizer
PIDI
Disha Pharma
Jingfeng Zhiyao
Yashica Pharma
Apotex
Glipizide Segment by Type
Glipizide Tablets
Glipizide Sustained Release Tablets
Others
Glipizide Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Glipizide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Glipizide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Glipizide market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Glipizide significant trends, drivers, influence factors in global and regions.
6. To analyze Glipizide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glipizide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glipizide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glipizide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Glipizide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Glipizide industry.
Chapter 3: Detailed analysis of Glipizide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Glipizide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Glipizide in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Glipizide Tablets
- Glipizide Sustained Release Tablets
- Others
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- CCPC
- TEVA
- Lukang Pharma
- United Laboratories
- Jumpcan
- Pfizer
- PIDI
- Disha Pharma
- Jingfeng Zhiyao
- Yashica Pharma
- Apotex
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Glipizide Sales Value (2021-2032)
- 1.2.2 Global Glipizide Sales Volume (2021-2032)
- 1.2.3 Global Glipizide Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Glipizide Market Dynamics
- 2.1 Glipizide Industry Trends
- 2.2 Glipizide Industry Drivers
- 2.3 Glipizide Industry Opportunities and Challenges
- 2.4 Glipizide Industry Restraints
3 Glipizide Market by Company
- 3.1 Global Glipizide Company Revenue Ranking in 2025
- 3.2 Global Glipizide Revenue by Company (2021-2026)
- 3.3 Global Glipizide Sales Volume by Company (2021-2026)
- 3.4 Global Glipizide Average Price by Company (2021-2026)
- 3.5 Global Glipizide Company Ranking (2024-2026)
- 3.6 Global Glipizide Company Manufacturing Base and Headquarters
- 3.7 Global Glipizide Company Product Type and Application
- 3.8 Global Glipizide Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Glipizide Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Glipizide Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Glipizide Market by Type
- 4.1 Glipizide Type Introduction
- 4.1.1 Glipizide Tablets
- 4.1.2 Glipizide Sustained Release Tablets
- 4.1.3 Others
- 4.2 Global Glipizide Sales Volume by Type
- 4.2.1 Global Glipizide Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Glipizide Sales Volume by Type (2021-2032)
- 4.2.3 Global Glipizide Sales Volume Share by Type (2021-2032)
- 4.3 Global Glipizide Sales Value by Type
- 4.3.1 Global Glipizide Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Glipizide Sales Value by Type (2021-2032)
- 4.3.3 Global Glipizide Sales Value Share by Type (2021-2032)
5 Glipizide Market by Application
- 5.1 Glipizide Application Introduction
- 5.1.1 Hospital Pharmacies
- 5.1.2 Online Pharmacies
- 5.1.3 Retail Pharmacies
- 5.2 Global Glipizide Sales Volume by Application
- 5.2.1 Global Glipizide Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Glipizide Sales Volume by Application (2021-2032)
- 5.2.3 Global Glipizide Sales Volume Share by Application (2021-2032)
- 5.3 Global Glipizide Sales Value by Application
- 5.3.1 Global Glipizide Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Glipizide Sales Value by Application (2021-2032)
- 5.3.3 Global Glipizide Sales Value Share by Application (2021-2032)
6 Glipizide Regional Sales and Value Analysis
- 6.1 Global Glipizide Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Glipizide Sales by Region (2021-2032)
- 6.2.1 Global Glipizide Sales by Region: 2021-2026
- 6.2.2 Global Glipizide Sales by Region (2027-2032)
- 6.3 Global Glipizide Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Glipizide Sales Value by Region (2021-2032)
- 6.4.1 Global Glipizide Sales Value by Region: 2021-2026
- 6.4.2 Global Glipizide Sales Value by Region (2027-2032)
- 6.5 Global Glipizide Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Glipizide Sales Value (2021-2032)
- 6.6.2 North America Glipizide Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Glipizide Sales Value (2021-2032)
- 6.7.2 Europe Glipizide Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Glipizide Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Glipizide Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Glipizide Sales Value (2021-2032)
- 6.9.2 South America Glipizide Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Glipizide Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Glipizide Sales Value Share by Country, 2025 VS 2032
7 Glipizide Country-level Sales and Value Analysis
- 7.1 Global Glipizide Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Glipizide Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Glipizide Sales by Country (2021-2032)
- 7.3.1 Global Glipizide Sales by Country (2021-2026)
- 7.3.2 Global Glipizide Sales by Country (2027-2032)
- 7.4 Global Glipizide Sales Value by Country (2021-2032)
- 7.4.1 Global Glipizide Sales Value by Country (2021-2026)
- 7.4.2 Global Glipizide Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Glipizide Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Glipizide Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Glipizide Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Glipizide Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Glipizide Sales Value Growth Rate (2021-2032)
- 7.9.2 France Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Glipizide Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Glipizide Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Glipizide Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Glipizide Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Glipizide Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Glipizide Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Glipizide Sales Value Growth Rate (2021-2032)
- 7.16.2 China Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Glipizide Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Glipizide Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Glipizide Sales Value Growth Rate (2021-2032)
- 7.19.2 India Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Glipizide Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Glipizide Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Glipizide Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Glipizide Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Glipizide Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Glipizide Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Glipizide Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Glipizide Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Glipizide Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Glipizide Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Glipizide Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Glipizide Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Glipizide Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Glipizide Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Glipizide Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Glipizide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 CCPC
- 8.1.1 CCPC Company Information
- 8.1.2 CCPC Business Overview
- 8.1.3 CCPC Glipizide Sales, Value and Gross Margin (2021-2026)
- 8.1.4 CCPC Glipizide Product Portfolio
- 8.1.5 CCPC Recent Developments
- 8.2 TEVA
- 8.2.1 TEVA Company Information
- 8.2.2 TEVA Business Overview
- 8.2.3 TEVA Glipizide Sales, Value and Gross Margin (2021-2026)
- 8.2.4 TEVA Glipizide Product Portfolio
- 8.2.5 TEVA Recent Developments
- 8.3 Lukang Pharma
- 8.3.1 Lukang Pharma Company Information
- 8.3.2 Lukang Pharma Business Overview
- 8.3.3 Lukang Pharma Glipizide Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Lukang Pharma Glipizide Product Portfolio
- 8.3.5 Lukang Pharma Recent Developments
- 8.4 United Laboratories
- 8.4.1 United Laboratories Company Information
- 8.4.2 United Laboratories Business Overview
- 8.4.3 United Laboratories Glipizide Sales, Value and Gross Margin (2021-2026)
- 8.4.4 United Laboratories Glipizide Product Portfolio
- 8.4.5 United Laboratories Recent Developments
- 8.5 Jumpcan
- 8.5.1 Jumpcan Company Information
- 8.5.2 Jumpcan Business Overview
- 8.5.3 Jumpcan Glipizide Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Jumpcan Glipizide Product Portfolio
- 8.5.5 Jumpcan Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Glipizide Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Pfizer Glipizide Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 PIDI
- 8.7.1 PIDI Company Information
- 8.7.2 PIDI Business Overview
- 8.7.3 PIDI Glipizide Sales, Value and Gross Margin (2021-2026)
- 8.7.4 PIDI Glipizide Product Portfolio
- 8.7.5 PIDI Recent Developments
- 8.8 Disha Pharma
- 8.8.1 Disha Pharma Company Information
- 8.8.2 Disha Pharma Business Overview
- 8.8.3 Disha Pharma Glipizide Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Disha Pharma Glipizide Product Portfolio
- 8.8.5 Disha Pharma Recent Developments
- 8.9 Jingfeng Zhiyao
- 8.9.1 Jingfeng Zhiyao Company Information
- 8.9.2 Jingfeng Zhiyao Business Overview
- 8.9.3 Jingfeng Zhiyao Glipizide Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Jingfeng Zhiyao Glipizide Product Portfolio
- 8.9.5 Jingfeng Zhiyao Recent Developments
- 8.10 Yashica Pharma
- 8.10.1 Yashica Pharma Company Information
- 8.10.2 Yashica Pharma Business Overview
- 8.10.3 Yashica Pharma Glipizide Sales, Value and Gross Margin (2021-2026)
- 8.10.4 Yashica Pharma Glipizide Product Portfolio
- 8.10.5 Yashica Pharma Recent Developments
- 8.11 Apotex
- 8.11.1 Apotex Company Information
- 8.11.2 Apotex Business Overview
- 8.11.3 Apotex Glipizide Sales, Value and Gross Margin (2021-2026)
- 8.11.4 Apotex Glipizide Product Portfolio
- 8.11.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Glipizide Value Chain Analysis
- 9.1.1 Glipizide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Glipizide Sales Mode & Process
- 9.2 Glipizide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Glipizide Distributors
- 9.2.3 Glipizide Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst